Key Quantitative Figures - Standalone (All amounts in ₹ Lakhs)

Quarter Ended June 30, 2026 (Unaudited):

  • Revenue from Operations: ₹2,352.23
  • Other Income: ₹53.97
  • Total Income: ₹2,406.20
  • Total Expenses: ₹381.97
  • Profit Before Tax: ₹2,024.23
  • Tax Expense: ₹521.25 (Current Tax: ₹516.82, Deferred Tax: ₹4.43)
  • Net Profit for the Period: ₹1,502.98
  • Total Comprehensive Income: ₹1,502.98
  • Paid-up Equity Share Capital: ₹4,378.79
  • Earnings Per Share (Basic & Diluted): ₹0.34

Comparatives:

  • Quarter Ended March 31, 2026 (Audited): Net Loss of ₹(172.67); EPS (₹0.04)
  • Quarter Ended June 30, 2025 (Unaudited): Net Profit of ₹102.96; EPS ₹0.02
  • Year Ended March 31, 2026 (Audited): Net Profit of ₹2,200.79; EPS ₹0.50

Key Quantitative Figures - Consolidated (All amounts in ₹ Lakhs)

Quarter Ended June 30, 2026 (Unaudited):

  • Revenue from Operations: ₹2,352.23
  • Other Income: ₹53.97
  • Total Income: ₹2,406.20
  • Total Expenses: ₹589.02
  • Profit Before Tax: ₹1,817.18
  • Tax Expense: ₹521.33 (Current Tax: ₹516.90, Deferred Tax: ₹4.43)
  • Net Profit for the Period: ₹1,295.85
  • Total Comprehensive Income: ₹1,295.85
  • Paid-up Equity Share Capital: ₹4,378.79
  • Earnings Per Share (Basic & Diluted): ₹0.30

Comparatives:

  • Quarter Ended March 31, 2026 (Audited): Net Loss of ₹(171.62); EPS (₹0.04)
  • Quarter Ended June 30, 2025 (Unaudited): Net Profit of ₹102.96; EPS ₹0.02
  • Year Ended March 31, 2026 (Audited): Net Profit of ₹2,205.84; EPS ₹0.50

Segment Information (Standalone & Consolidated)

The company operates in two segments:

1. Shukra Pharmaceutical

2. Shukra MedTech (effective from October 1, 2025)

For the quarter, the Pharmaceutical segment reported revenue of ₹2,406.20 lakhs. Segment assets and liabilities are detailed in the provided tables for both standalone and consolidated entities.

Dates and Parties Involved

  • Board Meeting Date: August 12, 2026 (commenced at 1:30 PM, concluded at 2:30 PM)
  • Period Reported: Quarter ended June 30, 2026
  • Statutory Auditors: M/s Shah Sanghvi and Associates, Chartered Accountants (FRN:140107W)
  • Reviewing Authority: Audit Committee and Board of Directors
  • Signatories: Dakshesh Shah, Managing Director; Ravi Shah, Partner at Shah Sanghvi & Associates

Other Business Reviewed

The Board also reviewed other business of the company, though specifics were not disclosed.

Investor Grievance

During the quarter ended June 30, 2026, the company received 0 investor complaints. Consequently, no investor complaints were pending as of June 30, 2026.

Auditor's Review

The unaudited financial results were reviewed by the statutory auditors, Shah Sanghvi & Associates. Their review report, issued pursuant to Standard on Review Engagement (SRE) 2410, states that nothing has come to their attention to believe the statements contain any material misstatement. The consolidated results include the holding company and its four subsidiaries.